Category - Feature

Feature

Strong scientific rationale for IntelGenx montelukast program

By Len Zehrs IntelGenx (OTCQX:IGXT; TSXV:IGX), which has initiated a proof-of-concept study with its Montelukast VersaFilm in patients with Alzheimer’s disease, using a drug originally approved in 1997 for the...

February 13, 2018

Feature

Eiger BioPharma has multiple catalysts in orphan diseases in 2018

By Len Zehrs Despite a failed Phase 2 trial in pulmonary arterial hypertension (PAH), Eiger BioPharmaceuticals (NASDAQ:EIGR) still has multiple shots on goal with its targeted therapies for orphan diseases, including a...

February 6, 2018

Feature

Spartan Bioscience takes aim at Legionnaires’ disease

By Len Zehrs Closely-held Spartan Bioscience’s recently launched an on-site rapid DNA test for Legionnaires’ disease that has the potential to eliminate lengthy culture testing in third-party labs and detect the...

January 30, 2018

Feature

FDA advisory vote on TLANDO not a knockout for Lipocine

By Len Zehrs Although Lipocine (NASDAQ:LPCN) is disappointed by a FDA advisory committee vote against the benefit/risk profile of TLANDO, its oral testosterone replacement therapy (TRT), the company believes there is...

January 23, 2018

Feature

Chi-Med transforming into fully integrated pharma

By Len Zehrs After 17 years of blistering growth in China, Hutchison China Meditech (Chi-Med) (AIM, NASDAQ:HCM) is taking center stage as a global drug innovator, with a fully integrated pipeline approaching regulatory...

January 9, 2018

Feature

IntelGenx to regain WW rights to commercialize Rizaport

By Len Zehrs Early in January, IntelGenx (OTCQX:IGXT; TSXV:IGX) will regain exclusive worldwide rights to develop and commercialize its Rizaport oral thin-film treatment of acute migraines. The move follows a decision...

December 19, 2017

Feature

Soricimed planning to initiate Phase 1b/2a solid tumor trial in Q2

By Len Zehrs Closely-held Soricimed Biopharma expects to initiate in the second quarter of 2018 a Phase 1b/2a clinical trial with its SOR-C13 drug candidate in patients with prostate cancer, including men who have...

December 12, 2017

Feature

Crescita targeting $50-million in revenue in 5 years

By Len Zehrs Crescita Therapeutics (TSX:CTX), is aiming to be a $50-million commercial dermatology company in the next five years, with a portfolio of non-prescription skincare products and prescription drug products...

December 5, 2017

Feature

BioLight dry eye subsidiary approaching CE Mark filing, U.S. pivotal trial

By Len Zehrs DiagnosTear, the dry eye diagnostic subsidiary of BioLight Life Sciences (TASE:BOLT), hopes to file by the end of 2017 for CE Mark approval in Europe and begin a pivotal trial in the U.S. in mid-2018 with...

November 28, 2017

Feature

GeNeuro pioneering HERVs against neurodegenerative and autoimmune diseases

By Len Zehrs Swiss-based GeNeuro (Euronext Paris: CH0308403085 – GNRO) is leveraging the biology of human endogenous retroviruses (HERVs) to stop the causes of neurodegenerative and autoimmune diseases, such as multiple...

November 21, 2017

Category - Feature

Subscribe